Antidepressant medication use, weight gain, and risk of type 2 diabetes: a population-based study.
OBJECTIVE
To examine antidepressant medication use as a risk factor for type 2 diabetes and weight gain.


METHODS
A series of nested studies within a prospective cohort of 151,347 working-aged men and women including 9,197 participants with continuing antidepressant medication, 224 with severe depression, and 851 with incident type 2 diabetes during a mean follow-up of 4.8 years, as indicated by national health and prescription registers (the Public Sector study, Finland 1995-2005).


RESULTS
In the first analysis, the case subjects were individuals with incident type 2 diabetes compared with matched diabetes-free control subjects. Antidepressant use of ≥ 200 defined daily doses was associated with a doubling of diabetes risk in both participants with no indication of severe depression (odds ratio 1.93 [95% CI 1.48-2.51]) and participants with severe depression (2.65 [1.31-5.39]). In further analyses, the exposed group was antidepressant users and the reference group was nonusers matched for depression-related characteristics. The 5-year absolute risk of diabetes was 1.1% for nonusers, 1.7% for individuals treated with 200-399 defined daily doses a year, and 2.3% for those with ≥ 400 defined daily doses (P(trend) < 0.0001). An average self-reported weight gain, based on repeated surveys, was 1.4 kg (2.5%) among nonusers and 2.5 kg (4.3%) among users of ≥ 200 defined daily doses (P(trend) < 0.0001). Separate analyses for tricyclic antidepressants and selective serotonin reuptake inhibitors replicated these findings.


CONCLUSIONS
In these data, continuing use of antidepressant medication was associated with an increased relative risk of type 2 diabetes, although the elevation in absolute risk was modest.
Kivimäki
Mika
M
Department of Epidemiology and Public Health, University College London, London, UK. m.kivimaki@ucl.ac.uk
Hamer
Mark
M
Batty
G David
GD
Geddes
John R
JR
Tabak
Adam G
AG
Pentti
Jaana
J
Virtanen
Marianna
M
Vahtera
Jussi
J
D000328:Adult; D000928:Antidepressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D003866:Depressive Disorder / Q000188:drug therapy; D003924:Diabetes Mellitus, Type 2 / Q000139:chemically induced* / Q000453:epidemiology*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012307:Risk Factors; D015430:Weight Gain / Q000187:drug effects*; D055815:Young Adult
D000928:Antidepressive Agents
JAMA. 2010 Jan 6;303(1):47-53
20051569
N Engl J Med. 2008 Jan 17;358(3):252-60
18199864
Am J Psychiatry. 2010 May;167(5):580-8
20123914
Lancet. 2003 Feb 22;361(9358):653-61
12606176
Am J Psychiatry. 2009 May;166(5):591-8
19339356
Int Clin Psychopharmacol. 2007 Nov;22(6):382-6
17917558
J Clin Psychiatry. 2003;64 Suppl 8:22-9
12892538
Eur J Clin Pharmacol. 2008 May;64(5):531-8
18196226
BMJ. 2008 Mar 8;336(7643):516-7
18319297
Psychosom Med. 1997 May-Jun;59(3):241-50
9178335
Arch Gen Psychiatry. 2009 Aug;66(8):848-56
19652124
Diabetes Res Clin Pract. 2008 Jan;79(1):61-7
17714823
J Clin Psychiatry. 2006 Dec;67(12):1974-82
17194277
BMJ. 2010 Mar 26;340:c1468
20348175
Diabetes Care. 2008 Mar;31(3):420-6
18071002
J Psychopharmacol. 2008 Sep;22(7):792-804
18308785
Diabetes Care. 2010 Jul;33(7):1471-6
20368411
PLoS Med. 2008 Feb;5(2):e45
18303940
Expert Opin Drug Saf. 2006 Jan;5(1):157-68
16370964